MAY 1 3 2002 Docket No. DIE01-NP002

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dietzschold

Group Art Unit: 1635

Examiner: Tara Washington

Serial No.:

Filed:

09/924,112

TRANSMITTAL OF INFORMATION

August 7, 2001

DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR

BEFORE MAILING OF FIRST OFFICE

**ACTION (37 CFR 1.97(b))** 

Title: "Rhabdovirus-based Vectors to

**Express High Levels of Functional:** 

**Human Antibodies**"

Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Respectfully submitted,

Date: May 7, 2002

Janet B. Smith, Ph.D.

Patent Agent

Registration No: 45,461

Thomas Jefferson University

Phone No: (215) 503-2386

1020 Walnut Street – 6<sup>th</sup> Floor Philadelphia, PA 19103-2793

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: May 7, 2002

Docket No.: DIRECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE, 3 2002

In re Application of:

**TECH CENTER 1600/2900** 

Dietzschold

Group Art Unit: 1635

Ex

Examiner: Tara Washington

Serial No.:

09/924,112

**INFORMATION** 

Filed:

August 7, 2001

DISCLOSURE STATEMENT

Title:

"Rhabdovirus-based Vectors:

to Express High Levels of

Functional Human

Antibodies"

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Dear Sir:

## List Of Sections Forming Part Of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

:

- 1. Preliminary Statements
- 2. Form PTO 1449 (Modified)
- 3. Copies of Listed Information Items Accompanying This Statement
- 4. Identification of Person(s) Making This Information Disclosure Statement

## Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

05/10/2002 HNOOR1

00000115 500491 09924112

01 FC:126

180.00 CH



# RECEIVED

MAY 1 3 2002

**TECH CENTER 1600/2900** 

#### **CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service as first class mail in an envelope addressed to: Box Issue Fee, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date:

Janyce Lingo

#### Section 2. Form PTO - 1449 (Continued)

2002

1600/2900

(Modi	ŕ	Patent and Trade  nformation Disclosure tatement by Applicant e several Sheets if necessa		✓ \  Annlica	lo.: 09/924 nt: DIET Pate: Augus 1635	ZCHO st 7, 20	LD, Be	TECH-CENTER		
	·		U.S. *	DOCUMEN'	ΓS			· · · · · · · · · · · · · · · · · · ·		
Exmr Initial		Patent Number	Issue Date Patentee		Cla		Sub- Class	Filing Date If Appropriate		
		FOREIGN PATENT		LISHED FOREIGN	PATENT AP	PLICA	ATION			
Exmr Initial		Document Number	Publn Date* Country or Patent Off		Office C	lass	Sub- Class	Translation? Yes No		
		OTHER DOCUMENT								
	AA	Whitelam, G., Cockbur	n, W., &	Owen, M. "Antibody	ite, Place of F Production in	ublica Transg	tion**) genic Pla	ants."		
	AB	Biochemical Society Transactions 22: 940-949, 1994.  Habel, K. "Isogeneic Versus Allogeneic Antiserum in the Prophylaxis of Experimental Rabies."  Bulletin of the World Health Organization 38: 383-387, 1968.								
	AC	Schnell, M., Mebatsion, T., & Conzelmann, K. "Infectious Rabies Viruses From Cloned cDNA."  The EMBO Journal 13 (18): 4195-4203, 1994.								
	AD	Arakawa, F., Haruno, M., Kuroki, M., Kanda, H., Watanabe, T., Misumi, Y., & Matsuoka, Y. "Construction and Expression of Two Mouse-human Chimeric Antibodies with High Specificity and Affinity for Carcinoembryonic Antigen." <i>Hybridoma</i> 12 (4): 365-379, 1993.								
	AE	Ueki, Y., Goldfarb, I., Harindranath, N., Gore, M., Koprowski, H., Notkins, A., & Casali, P. "Clonal analysis of a Human Antibody Response." The Journal of Experimental Medicine 171: 19-34, 1990.								
	AF	Dietzschold, B., Gore, M., Casali, P., Ueki, Y., Rupprecht, C., Notkins, A., & Koprowski, H. "Biological characterization of Human Monoclonal Antibodies to Rabies Virus." <i>Journal of Virology</i> 64 (6): 3087-3090, 1990.								
	AG	Beidler, C., Ludwig, J., Cardenas, J., Phelps, J., Papworth, C., Melcher, E., Sierzega, M., Myers, L., Unger, B., Fisher, M., David, G., & Johnson, M. "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen." <i>Journal of Immunology</i> 141 (11) 4053-4060, 1988.								
	АН	Champion, J., Kean, R., Rupprecht, C., Notkins, A., Koprowski, H., Dietzschold, B., & Hooper, D. "The Development of Monoclonal Human Rabies Virus-neutralizing Antibodies as a Substitute for Pooled Human Immune Globulin in the Prophylactic Treatment of Rabies Virus Exposure."  Journal of Immunology 235: 81-90, 2000.								
	AI	Buchholz, U., Finke, S., & Conzelmann, K. "Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter." <i>Journal of Virology</i> 73 (1): 251-259, 1999.								
Examine	er				Date Conside	ered				

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.

## Section 2. Form PTO - 14-9 (Continued)

RECEIVED

MPAYOR 31 2002

TECH CENTER 1800 2900

Form F (Modif	ied)- Pa	449 U.S. Department atent and Trademark Office formation Disclosure atement by Applicant eseveral Sheets if necessary	e	2002 ×C2	Docket No:  Serial No.:  Applicant:  Filing Date:  Art No.  Examiner	1033	NP002 112 SCHOL <b>1</b> 7, 2001 Vashington	CH CENTER 1		
		77			CUMENTS					
Exmr		T	Issue	ATEMI DO	COMENTS		Sub-	Filing Date		
Initial		Patent Number	Date	Patentee		Class	Class	If Appropriate		
	<u> </u>	FOREIGN PATENT	OR PUR	LISHED F	OREIGN PATER	JT A PPLI	CATION			
Exmr	T	Document Number	Publn			TALLE	Sub-	Translation?		
Initial			Date*	Country or Patent Office		Class	Class	Yes No		
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)										
	AJ	Morimoto, K., Hooper, D., Carbaugh, H., Fu, Z., Koprowski, H., & Dietzschold, B. "Rabies Virus Quasispecies: Implications for Pathogenesis." <i>Proceedings of the National Academy of Science, USA 95</i> : 3152-3156, 1998.								
	AK	Schnell, M., Foley, H., Siler, C., McGettigan, J., Dietzschold, B., & Pomerantz, R. "Recombinant Rabies Virus as Potential Live-viral Vaccines for HIV-1." <i>Proceedings of the National Academy of Science, USA</i> 97 (7): 3544-3549, 2000.								
	AL	Steele, J. "Rabies in the Americas and Remarks on Global Aspects." Reviews of Infectious Diseases 10 (4): \$585-\$597, 1988.								
	AM	Liang, M., Guttieri, M., Lundkvist, A., & Schmaljohn, C. "Baculovirus Expression of a Human G2-Specific, Neutralizing IgG Monoclonal Antibody to Puumala Virus." Virology 235: 252-260, 1977.								
	AN	Finke, S., & Conzelmann, K. "Virus Promoters Determine Interference by Defective RNAs: Selective Amplification of Mini-RNA Vectors and Rescue from cDNA by a 3' Copy-back Ambisense Rabies Virus." Journal of Virology 73 (5): 3818-3825, 1999.								
	AO	Ovens, R., & Young, R. "The Genetic Engineering of Monoclonal Antibodies." Journal of Immunological Methods 168: 149-165, 1994.								
	AP	Dietzschold, B., Morimoto, K., Hooper, D., Smith, J., Rupprecht, C., & Koprowski, H. "Genotypic & Phenotypic Diversity of Rabies Virus Variants Involved in Human Rabies: Implications for Postexposure Prophylaxis." <i>Journal of HumanVirology</i> 3 (1): 50-57, 2000.								
	AQ	Wilde, H., Choomkasien, P., Hemachudha, T., Supich, C., & Chutivongse, S. "Failure of Rabies Postexposure Treatment in Thailand." Vaccine 7: 49-52, 1989.								
				·						
						-				
Examin	er				Date	Considered	<u> </u>			
EVARAL	NED	Initial sitution consider								

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO - 1449)

Use publication date indicated on the patent or published application. 37 CFR 1.98(b).

The place or publication refers to the name of the journal, magazine or other publication in which the article was published. Notice of January 9, 1992, 1135 O.G. 13 to 25 at 20.